Ocumension Therapeutics (1477.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG674111011
Ocumension Therapeutics financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 417.00 m CNY | 804.35 m CNY |
| Gross profit | 225.00 m CNY | 420.00 m CNY |
| EBIT | -306.00 m CNY | -186.00 m CNY |
| Net income | -268.00 m CNY | -158.82 m CNY |
| Diluted EPS – continuing operations | -0.37 CNY | -0.23 CNY |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ocumension Therapeutics
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing. It also develops drugs in Phase III clinical trial, including OT-101 for myopia, OT-802 for presbyopia, OT-211 for dry eye disease, and OT-301 for glaucoma; and drugs in Phase I/II clinical trial, such as OT-703 for diabetic macular edema, OT-202 for dry eye disease, and OT-601-C for the treatment of ocular inflammation. In addition, the company engages in the development of drugs in preclinical stage comprising OT-701 for wet age-related macular degeneration, OT-1601 for retinitis pigmentosa and dry age-related macular degeneration, OT-1602 for optic neuritis, and OT-503 for dry eye disease. Further, it is involved in trading of pharmaceutical products; and plant construction. The company was founded in 2017 and is based in Suzhou, China.
More stocks
- Atria Oyj (ATRAV.HE)
- Cogna Educação S.A (COGN3.SA)
- UNITED STATES ANTIMONY CORP (UAMY)
- Guangzhou Tongda Auto Electric Co Ltd (603390.SS)
- Calfrac Well Services Ltd. (CFW.TO)
- Jiangxi Naipu Mining Machinery (300818.SZ)
- Song Chuan Precision Co., Ltd. (7788.TW)
- Acast AB (publ) (ACAST.ST)
- Senseonics Holdings, Inc. (SENS)
- Taiwan Chinsan Electronic Industrial Co Ltd (8042.TWO)
- Jee Technology Co. Ltd. A (688162.SS)
- FrontView REIT, Inc. (FVR)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.